tiprankstipranks
Advertisement
Advertisement

TKPHF Stock Latest News

Takeda upgraded to Outperform from Market Perform at Bernstein
The FlyTakeda upgraded to Outperform from Market Perform at Bernstein
2d ago
TAK
Denali Therapeutics regains full rights to DNL593
PremiumThe Fly
Denali Therapeutics regains full rights to DNL593
4d ago
TAK
DNLI
Abivax appoints Michael Nesrallah as chief commercial officer
PremiumThe Fly
Abivax appoints Michael Nesrallah as chief commercial officer
8d ago
TAK
ABVX
Axsome Therapeutics enters TAK-063 asset purchase agreement with Takeda
PremiumThe Fly
Axsome Therapeutics enters TAK-063 asset purchase agreement with Takeda
9d ago
TAK
AXSM
Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
PremiumThe Fly
Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
11d ago
JNJ
TAK
Alumis price target raised to $55 from $50 at Oppenheimer
PremiumThe FlyAlumis price target raised to $55 from $50 at Oppenheimer
11d ago
JNJ
TAK
Takeda’s Oral Psoriasis Drug Zasocitinib Shows Strong Phase 3 Results
Premium
Company Announcements
Takeda’s Oral Psoriasis Drug Zasocitinib Shows Strong Phase 3 Results
11d ago
Takeda announces new data from Phase 3 studies of TAK-279
Premium
The Fly
Takeda announces new data from Phase 3 studies of TAK-279
12d ago
TAK
Takeda Sets June CEO Handover to Julie Kim and Overhauls Board Line-up
PremiumCompany Announcements
Takeda Sets June CEO Handover to Julie Kim and Overhauls Board Line-up
15d ago
Takeda Unveils Cost-Saving Transformation to Fund Next Wave of Drug Launches
PremiumCompany Announcements
Takeda Unveils Cost-Saving Transformation to Fund Next Wave of Drug Launches
16d ago
Alkermes price target lowered to $43 from $45 at Piper Sandler
PremiumThe Fly
Alkermes price target lowered to $43 from $45 at Piper Sandler
17d ago
TAK
ALKS
Protagonist Therapeutics price target raised to $100 from $86 at Wedbush
PremiumThe Fly
Protagonist Therapeutics price target raised to $100 from $86 at Wedbush
1M ago
TAK
PTGX
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
PremiumThe FlyTakeda, Protagonist announce FDA acceptance of rusfertide new drug application
1M ago
TAK
PTGX
Takeda and Protagonist Win FDA Priority Review for First-in-Class Polycythemia Vera Drug
Premium
Company Announcements
Takeda and Protagonist Win FDA Priority Review for First-in-Class Polycythemia Vera Drug
1M ago
Boston Scientific names Cathy Smith, Christophe Weber to board of directors
Premium
The Fly
Boston Scientific names Cathy Smith, Christophe Weber to board of directors
2M ago
BSX
TAK
Takeda announces data from Phase 3 KEPLER trial of ENTYVIO
PremiumThe Fly
Takeda announces data from Phase 3 KEPLER trial of ENTYVIO
2M ago
TAK
Takeda granted Priority Review for oveporexton by FDA
PremiumThe Fly
Takeda granted Priority Review for oveporexton by FDA
2M ago
TAK
Takeda Wins FDA Priority Review for Potential First-in-Class Narcolepsy Drug
PremiumCompany Announcements
Takeda Wins FDA Priority Review for Potential First-in-Class Narcolepsy Drug
2M ago
Takeda raises FY25 core EPS view to 486 yen from 479 yen
PremiumThe Fly
Takeda raises FY25 core EPS view to 486 yen from 479 yen
2M ago
TAK
Takeda reports Q3 core EPS 428 yen vs. 443 yen last year
PremiumThe FlyTakeda reports Q3 core EPS 428 yen vs. 443 yen last year
2M ago
TAK
Takeda Posts Lower Nine-Month Revenue but Higher Profit, Lifts Dividend and Trims Growth Outlook
Premium
Company Announcements
Takeda Posts Lower Nine-Month Revenue but Higher Profit, Lifts Dividend and Trims Growth Outlook
2M ago
TKPHF Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
TKPHF Upcoming Earnings Report: What to Expect?
2M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >